Pacer Advisors
PTCT icon

Pacer Advisors’s PTC Therapeutics PTCT Stock Holding History

Pacer Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51K Buy
+629
New +$45.4K ﹤0.01% 2037
2026
Q1 		– Sell
-235,653
Closed -$17.9M – 2353
2025
Q4 		$17.9M Sell
235,653
-268,313
-53% -$19.5M 0.05% 343
2025
Q3 		$30.9M Sell
503,966
-236,851
-32% -$12.3M 0.08% 240
2025
Q2 		$36.2M Buy
+740,817
New +$35.2M 0.09% 213
2024
Q3 		– Sell
-571
Closed -$17.5K – 2662
2024
Q2 		$17.5K Sell
571
-796
-58% -$25.8K ﹤0.01% 3452
2024
Q1 		$39.8K Buy
+1,367
New +$38.3K ﹤0.01% 3262
2021
Q2 		– Sell
-1,327
Closed -$63K – 1518
2021
Q1 		$63K Sell
1,327
-704
-35% -$41.8K ﹤0.01% 1410
2020
Q4 		$124K Sell
2,031
-102
-5% -$6.01K ﹤0.01% 1331
2020
Q3 		$100K Buy
+2,133
New +$105K ﹤0.01% 1248
2018
Q4 		– Sell
-6,384
Closed -$300K – 927
2018
Q3 		$300K Buy
+6,384
New +$264K 0.01% 953
2018
Q1 		– Sell
-1,550
Closed -$26K – 1109
2017
Q4 		$26K Buy
+1,550
New +$26.2K ﹤0.01% 1082

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Pacer Advisors's PTCT Position: Q2 2026 in Review

Pacer Advisors opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 629 shares worth $51K. The stake represents ﹤0.01% of the portfolio and ranks #2037 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in PTCT as recently as Q4 2025.

Pacer Advisors first reported a position in PTCT in Q4 2017 and has held it in 11 quarters since. The position peaked at $36.2M in Q2 2025. 383 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Pacer Advisors held 629 shares of PTC Therapeutics worth $51K as of Q2 2026.
  • PTC Therapeutics was a new Pacer Advisors position in Q2 2026.
  • PTC Therapeutics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2037 holding.
  • Pacer Advisors first reported a position in PTC Therapeutics in Q4 2017 and has held it in 11 quarters since.
  • Pacer Advisors's PTC Therapeutics position peaked at $36.2M in Q2 2025.
  • 383 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.